Methylation profile of triple-negative breast carcinomas

Oncogenesis

Volumn 1, Issue 7, 2012, Pages

  Branham, M T ^a,c   Marzese, D M ^a,c   Laurito, S R ^a,c   Gago, F E ^b,c   Orozco, J I ^c   Tello, O M ^a,c   Vargas Roig, L M ^a   Roque M ^a,c  

^a INSTITUTO ARGENTINO DE NIVOLOGÍA   (Argentina)

^b Instituto Gineco Mamario   (Argentina)

^c UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

Author keywords

CpG island; methylation profile; triple negative breast tumors

Indexed keywords

CACNA1A PROTEIN; CACNA1G PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DLC1 PROTEIN; GLUTATHIONE TRANSFERASE P1; HERMES ANTIGEN; ID4 PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MISMATCH REPAIR PROTEIN PMS2; PROTEIN; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH3; PROTEIN MSH6; PROTEIN P73; RETINOBLASTOMA PROTEIN; TWIST1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; CPG ISLAND; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METHYLATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; TRIPLE NEGATIVE BREAST CANCER;

EID: 84868283687     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2012.17     Document Type: Article

References (22)

1. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12(Suppl 2): S3.
2. Chen JQ, Russo J. ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches. Biochim Biophys Acta 2009; 1796: 162-175.
3. Reddy KB. Triple-negative breast cancers: an updated review on treatment options. Curr Oncol 2011; 18: e173-e179.
4. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010; 7: 683-692.
5. Kreike B, van KM, Horlings H, Weigelt B, Peterse H, Bartelink H et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.
6. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32. (Pubitemid 46120191)
7. Kashiwagi S, Yashiro M, Takashima T, Nomura S, Noda S, Kawajiri H et al. Significance of E-cadherin expression in triple-negative breast cancer. Br J Cancer 2010; 103: 249-255.
8. Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14: 8010-8018.
9. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010; 12: R68.
10. Carey LA. Directed therapy of subtypes of triple-negative breast cancer. Oncologist 2011; 16(Suppl 1): 71-78.
11. Esteller M. Epigenetics in cancer. N Engl J Med 2008; 358: 1148-1159.
12. Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol 2009; 19: 165-171.
13. Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ et al. Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 2005; 33: e128.
14. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 2002; 30: e57.
15. Marzese DM, Gago FE, Vargas-Roig LM, Roque M. Simultaneous analysis of the methylation profile of 26 cancer related regions in invasive breast carcinomas by MS-MLPA and drMS-MLPA. Mol Cell Probes 2010; 24: 271-280.
16. Martin SA, Lord CJ, Ashworth A. Therapeutic targeting of the DNA mismatch repair pathway. Clin Cancer Res 2010; 16: 5107-5113.
17. Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I et al. Methylation of O (6)-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat 2012 (e-pub ahead of print).
18. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de TN, Weller M et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003. (Pubitemid 40349502)
19. Kim YS, Kim SH, Cho J, Kim JW, Chang JH, Kim DS et al. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Int J Radiat Oncol Biol Phys 2012.
20. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91: 179-186. (Pubitemid 40684930)
21. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-2132. (Pubitemid 46514749)
22. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009; 19: 1639-1645.